About
About CABIO Biotech(Wuhan) Co., Ltd
Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production, and sale of functional ingredients and bio-based products in China and internationally. The company offers polyunsaturated fatty acids, including arachidonic acid (ARA) and docosahexaenoic acid (DHA); terpenoids, such as beta (ß)-carotene and astaxanthin; and carbohydrates, such as N-acetylneuraminic acid and human milk oligosaccharides. Its products are used in human nutrition, including early life nutrition and dietary supplements; animal nutrition, such as economic animal and pet nutrition; personal care and cosmetics; and synthetic biology applications. The company also engages in the production of food additives and other food products; consulting services in bioengineering, environmental protection, healthcare, and food technologies; research, development, and sale of biological feed and feed additives; food wholesale; technology development; and venture capital activities. Cabio Biotech (Wuhan) Co., Ltd. was founded in 1999 and is based in Wuhan, the People's Republic of China.
Visit company website
5 years, 5 months ago
CABIO Biotech(Wuhan) Co., Ltd is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 19.2% more expensive than other stocks from the None sector with a price to sales ratio of 14.8.
CABIO Biotech(Wuhan) Co., Ltd's total revenue rose by 8.5% to $87M since the same quarter in the previous year.
Its net income has dropped by 7.6% to $20M since the same quarter in the previous year.
Finally, its free cash flow fell by 21.3% to $42M since the same quarter in the previous year.
Based on the above factors, CABIO Biotech(Wuhan) Co., Ltd gets an overall score of 2/5.